CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

肺癌围术期研究CheckMate-77T报捷，欧狄沃用于可切除肺癌再证疗效医药

IJMS, Free Full-Text

Perioperative Nivolumab Improves EFS in NSCLC - Cancer Therapy Advisor

PharmaScroll on LinkedIn: Phase 3 Trial Shows Neoadjuvant

Gaining an Advantage Over NSCLC: How to Achieve the Greatest

Perioperative Opdivo regimen succeeds in non-metastatic NSCLC

New data support perioperative nivolumab for NSCLC

Perioperative Nivolumab Plus Chemotherapy Improves Event-Free

Giulio Draetta: Tremendously proud of Tina Cascone for her

JCM, Free Full-Text

Shaheenah Dawood on LinkedIn: #nsclc #oncologyresearch

Bristol Myers joins AstraZeneca, Merck in touting positive lung

CheckMate-77T Trial Meets Primary EFS End Point in Resectable NSCLC

The earlier, the better? A review of neoadjuvant immunotherapy in